Insider Transactions in Q1 2024 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.88%
|
$27,000
$27.5 P/Share
|
|
Mar 19
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.97%
|
$28,000
$28.0 P/Share
|
|
Mar 18
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Direct |
1,000
+3.06%
|
$27,000
$27.49 P/Share
|
|
Mar 06
2024
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
40,000
-9.08%
|
$1,400,000
$35.19 P/Share
|
|
Jan 31
2024
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,499
-0.76%
|
$1,839,968
$32.43 P/Share
|
|
Jan 31
2024
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,499
+1.5%
|
$804,986
$14.54 P/Share
|
|
Jan 12
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
7,940
-1.83%
|
$285,840
$36.92 P/Share
|
|
Jan 11
2024
|
Victoria Vakiener Director |
SELL
Open market or private sale
|
Direct |
4,720
-6.59%
|
$179,360
$38.36 P/Share
|
|
Jan 11
2024
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
3,147
-2.49%
|
$119,586
$38.22 P/Share
|
|
Jan 11
2024
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
3,934
-3.86%
|
$149,492
$38.2 P/Share
|
|
Jan 11
2024
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
2,911
-1.1%
|
$110,618
$38.15 P/Share
|
|
Jan 05
2024
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,303
-1.35%
|
$282,302
$34.93 P/Share
|
|
Jan 05
2024
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
16,104
-1.19%
|
$547,536
$34.89 P/Share
|
|
Jan 05
2024
|
Tracie Oliver Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
74
-0.05%
|
$2,442
$33.89 P/Share
|
|
Jan 05
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
32,143
-3.35%
|
$1,092,862
$34.9 P/Share
|
|
Jan 05
2024
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
22,841
-1.58%
|
$776,594
$34.88 P/Share
|
|
Jan 04
2024
|
Martin Javier San Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+26.61%
|
-
|
|
Jan 04
2024
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+14.11%
|
-
|
|
Jan 04
2024
|
Tracie Oliver Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+35.45%
|
-
|
|
Jan 04
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+23.01%
|
-
|
|
Jan 04
2024
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+14.85%
|
-
|
|
Jan 04
2024
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
1,600
-0.4%
|
$51,200
$32.63 P/Share
|
|
Jan 03
2024
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
6,300
-1.16%
|
$201,600
$32.54 P/Share
|
|
Jan 03
2024
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
8,749
-0.53%
|
$279,968
$32.6 P/Share
|
|
Jan 02
2024
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,952
-0.13%
|
$298,560
$31.0 P/Share
|